A carregar...
Targeted therapy in Advanced Bladder cancer- what have we learned?
Urothelial carcinoma (UC) is the second most common genitourinary malignancy in the United States. In the metastatic setting, cisplatin-based chemotherapy results in a median overall survival (OS) of 12–15 months and remains the only standard of care for this disease. Despite advances in the treatme...
Na minha lista:
| Publicado no: | Urol Clin North Am |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939834/ https://ncbi.nlm.nih.gov/pubmed/25882566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ucl.2015.01.006 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|